Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
- PMID: 28362007
- PMCID: PMC5349019
- DOI: 10.15698/mic2016.03.482
Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
Keywords: Alzheimer’s; FDA; amyloid beta; drug; screen; yeast.
Conflict of interest statement
Conflict of interest: The authors declare no conflict of interest.
Figures
Comment on
-
Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs.Microb Cell. 2016 Jan 20;3(2):53-64. doi: 10.15698/mic2016.02.476. Microb Cell. 2016. PMID: 28357335 Free PMC article.
References
-
- Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol. 1984;2(6):357–369. - PubMed
-
- Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA. Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease. Acta Neuropathol. 1999;97(2):113–118. - PubMed
-
- Fogel H, Frere S, Segev O, Bharill S, Shapira I, Gazit N, O'Malley T, Slomowitz E, Berdichevsky Y, Walsh DM, Isacoff EY, Hirsch JA, Slutsky I. APP Homodimers Transduce an Amyloid-beta-Mediated Increase in Release Probability at Excitatory Synapses. Cell Rep. 2014;7(5):1560–1576. doi: 10.1016/j.celrep.2014.04.024. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources